January 14, 2013
New research reviews added! Visit the AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program.
Health Awareness Topics - January 2013
- Cervical Health Awareness Month (see related guidelines and guideline synthesis)
- National Glaucoma Awareness Month (see related guidelines)
- The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site .
U.S. Food and Drug Administration (FDA) Advisory
- January 10, 2013: Zolpidem Containing Products : FDA is notifying the public of new information about zolpidem, a widely prescribed insomnia drug. FDA recommends that the bedtime dose be lowered because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving. This announcement focuses on zolpidem products approved for bedtime use, which are marketed as generics and under the brand names Ambien, Ambien CR, Edluar, and Zolpimist.